更新于：2024-11-01

Papillary Renal Cell Carcinoma

乳状状肾细胞癌

更新于：2024-11-01

基本信息

别名

Chromophil Carcinoma of Kidney、Chromophil Carcinoma of the Kidney、Chromophil Renal Cell Carcinoma

+ [13]

简介

Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas. It can be hereditary or sporadic. The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y. The peak incidence is in the sixth and seven decades. It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma.

关联

项与乳状状肾细胞癌相关的药物

Savolitinib

赛沃替尼

靶点

c-Met

作用机制

c-Met抑制剂

在研机构

AstraZeneca PLC [+2]

原研机构

和记黄埔医药（上海）有限公司

在研适应症

MET外显子14跳变的非小细胞肺癌 [+12]

非在研适应症

晚期胃癌 [+5]

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2021-06-22

Pamiparib

帕米帕利

靶点

PARP1 x PARP2

作用机制

PARP1抑制剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2021-04-30

Durvalumab

度伐利尤单抗

靶点

PDL1

作用机制

PDL1抑制剂

在研机构

AstraZeneca PLC [+18]

原研机构

AstraZeneca UK Ltd.

在研适应症

晚期子宫内膜癌 [+159]

非在研适应症

急性髓性白血病 [+57]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2017-05-01

项与乳状状肾细胞癌相关的临床试验

NCT05665361 / Recruiting临床1/2期IIT

A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Background:
Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed.
Objective:
To test a pair of drugs (sasanlimab and palbociclib) in people with kidney cancers.
Eligibility:
People aged 18 years and older with kidney cancer; specifically, clear cell renal cell carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC).
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have an imaging scan and a test of their heart function. They may have a biopsy; that is, a sample of tissue will be cut from the tumor.
Participants will be treated in 28-day cycles for up to 2 years.
Palbociclib is a pill taken by mouth. Participants will take this drug once a day for 21 days during each 28-day treatment cycle. They will write down the dates and times they take these pills in a diary.
Sasanlimab is an injection under the skin. Participants will receive this injection on the first day of each treatment cycle.
Imaging scans and blood tests will be repeated throughout the treatment. Tumor biopsies may be repeated up to 3 times; these biopsies are optional.
Participants will have follow-up visits every month for 3 months after treatment ends. They will continue to have imaging scans every 3 months; these scans may be done close to home. The results can be sent to researchers.
Participants will remain in the study up to 6 years.

开始日期2024-04-24

申办/合作机构

National Cancer Institute

NCT06146777 / Not yet recruiting临床3期IIT

A Multicenter, Open, Prospective Study of Prognostic Value and Benefit From Adjuvant Immunotherapy of Stage III Papillary Renal Cell Carcinoma Based on Multi-classifier System

The goal of this trial is to test whether patients with stage III papillary renal cell carcinoma (pRCC) could benefit from adjuvant therapy or not. The investigators invented a multi-classifier system that was successfully categorise patients with stage III pRCC into high-risk and low-risk groups. Here the investigators randomly assign classifier-defined high risk patients of stage III pRCC into adjuvant pembrolizumab group placebo group. Disease-free survival and overall survival are the end points of observation.

开始日期2023-12-01

申办/合作机构

中山大学附属第一医院

NCT05411081 / Recruiting临床2期IIT

A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)

This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.

开始日期2023-03-24

申办/合作机构

National Cancer Institute

100 项与乳状状肾细胞癌相关的临床结果

登录后查看更多信息

100 项与乳状状肾细胞癌相关的转化医学

登录后查看更多信息

0 项与乳状状肾细胞癌相关的专利（医药）

登录后查看更多信息

2,271

项与乳状状肾细胞癌相关的文献（医药）

2024-12-31·Cancer Biology & Therapy

Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma

Article

作者: Altieri, Adrian D ; Mitra, Ramkrishna ; Abinader, Oliver ; Verrillo, Cecilia E ; Yu, Jindan ; Zhao, Jonathan ; Hooper, D Craig ; Hawkins, Adam ; Languino, Lucia R ; Naranjo, Nicole M ; Kennedy, Anne ; Kean, Rhonda ; Kelly, William K ; Testa, Anna ; Pickles, Maxwell W

Prostate cancer has heterogeneous growth patterns, and its prognosis is the poorest when it progresses to a neuroendocrine phenotype. Using bioinformatic analysis, we evaluated RNA expression of neuroendocrine genes in a panel of five different cancer types: prostate adenocarcinoma, breast cancer, kidney chromophobe, kidney renal clear cell carcinoma and kidney renal papillary cell carcinoma. Our results show that specific neuroendocrine genes are significantly dysregulated in these tumors, suggesting that they play an active role in cancer progression. Among others, synaptophysin (SYP), a conventional neuroendocrine marker, is upregulated in prostate adenocarcinoma (PRAD) and breast cancer (BRCA). Our analysis shows that SYP is enriched in small extracellular vesicles (sEVs) derived from plasma of PRAD patients, but it is absent in sEVs derived from plasma of healthy donors. Similarly, classical sEV markers are enriched in sEVs derived from plasma of prostate cancer patients, but weakly detectable in sEVs derived from plasma of healthy donors. Overall, our results pave the way to explore new strategies to diagnose these diseases based on the neuroendocrine gene expression in patient tumors or plasma sEVs.

2024-12-01·Molecular Therapy: Oncology

Exploring prognostic implications of miRNA signatures and telomere maintenance genes in kidney cancer

Article

作者: Hebbring, Scott ; Yerukala Sathipati, Srinivasulu ; Jeong, Sohyun ; Ho, Shinn-Ying ; Sharma, Rohit ; Sharma, Param ; Mayer, John

Kidney cancer, particularly clear cell renal cell carcinoma (KIRC), presents significant challenges in disease-specific survival. This study investigates the prognostic potential of microRNAs (miRNAs) in kidney cancers, including KIRC and kidney papillary cell carcinoma (KIRP), focusing on their interplay with telomere maintenance genes. Utilizing data from The Cancer Genome Atlas, miRNA expression profiles of 166 KIRC and 168 KIRP patients were analyzed. An evolutionary learning-based kidney survival estimator identified robust miRNA signatures predictive of 5-year survival for both cancer types. For KIRC, a 37-miRNA signature showed a correlation coefficient (R) of 0.82 and mean absolute error (MAE) of 0.65 years. Similarly, for KIRP, a 23-miRNA signature exhibited an R of 0.82 and MAE of 0.64 years, demonstrating comparable predictive accuracy. These signatures also displayed diagnostic potential with receiver operating characteristic curve values between 0.70 and 0.94. Bioinformatics analysis revealed targeting of key telomere-associated genes such as TERT, DKC1, CTC1, and RTEL1 by these miRNAs, implicating crucial pathways such as cellular senescence and proteoglycans in cancer. This study highlights the significant link between miRNAs and telomere genes in kidney cancer survival, offering insights for therapeutic targets and improved prognostic markers.

2024-11-01·Urology Case Reports

Synchronous bilateral papillary renal cell carcinoma in the native kidneys after 10 Years of renal transplantation: Report of a case and review of the literature

Article

作者: ARAIBI, H.A.Y.T.H.A.M. ; Araibi, Haytham

A case of synchronous bilateral native kidneys papillary RCC is presented in a 48 year old patient who underwent a living donor kidney transplant 10 years prior. He was on regular immunosuppressant therapy. Despite the long term follow-up, bilateral cystic and exophytic masses were incidentally found on CT scan. Subsequent bilateral open radical nephrectomy revealed papillary RCC in both kidneys.

项与乳状状肾细胞癌相关的新闻（医药）

2024-09-14

·Pharma CMC

贝达药业 EGFR/c-Met 双特异性抗体获批临床

9月10日，贝达药业发布公告，其自主研发的注射用 MCLA129 临床试验申请收到国家药监局签发的《受理通知书》（受理号：CXSL2400603），本次申请适应症为拟用于“晚期实体瘤（包括但不限于野生型结直肠癌、肝癌、头颈鳞癌、胰腺癌、原发不明腺癌以及鳞癌等晚期实体瘤）”。 MCLA-129 是一款针对表皮生长因子受体（EGFR）和细胞间质上皮转化因子（c-Met）双靶点的双特异性抗体，可同时阻断 EGFR 和 c-Met 的信号传导，抑制肿瘤的生长和存活，并且可经增强的抗体依赖的细胞介导的细胞毒性作用（ADCC）进一步提高对肿瘤细胞的杀伤潜能。其单品“拟用于 EGFR 或 MET 异常的晚期实体瘤患者”“联合甲磺酸贝福替尼胶囊在 EGFR 敏感突变晚期非小细胞肺癌患者”的临床试验已获得 NMPA 批准开展，目前正在推进中。 c-Met 由 MET 基因编码，是一种具有自主磷酸化活性的跨膜受体。c-Met 通路正常表达时促进组织的分化与修复，当调节异常时则促进肿瘤细胞的增殖与转移。该受体在肺癌、结直肠癌、胃癌、头颈癌、乳头状肾细胞癌、食管癌和脑癌等多种肿瘤中有异常过量的表达。同时，MET 过表达以及 MET 信号通路的激活是 EGFR耐药机制之一，EGFR/MET 双特异性抗体可同时阻断 EGFR/MET 通路，从而可能克服或延缓 EGFR 耐药，为肺癌、结直肠癌、胃癌、头颈癌、乳头状肾细胞癌、食管癌和脑癌等患者带来临床获益。目前，强生的EGFR/c-Met 双特异性抗体埃万妥单抗已经在美国获批上市，全球范围内若干 EGFR/c-Met 双特异性抗体尚处于临床研究阶段。内容来源于网络，如有侵权，请联系删除。

申请上市上市批准临床申请

2024-08-21

·生物探索

Cell | Cheng-Zhong Zhang/鲍春旸等揭示X染色体突变和癌症的性别差异之间的联系

引言多数癌症在发病率和预后等方面都存在显著的性别差异。癌症的性别差异(Cancer Sex Disparity)通常归因于激素水平和生活方式的不同。2024年8月20日，来自哈佛大学医学院/丹娜-法伯癌症研究所的Srinivas Viswanathan团队（肿瘤医学部）和Cheng-Zhong Zhang团队（数据科学部）在Cell上发表了题为“A genetic basis for cancer sex differences revealed in Xp11 translocation renal cell carcinoma”的学术论文。该研究首次揭示了癌症发病率的性别差异来源于性染色体产生的致癌突变。鲍春旸博士是论文的共同第一作者，并负责DNA拷贝数变异的分析以及肿瘤基因组进化的数据解读。在该论文中，研究人员通过全集因组测序和全转录组测序分析了X染色体在Xp11易位性肾细胞癌（Xp11 translocation renal cell carcinoma, tRCC）中的突变和进化，以及这些突变在男性和女性患者之间的差异。常见的肾癌，比如透明细胞肾细胞癌（clear cell renal cell carcinoma, ccRcc）或者乳头状肾细胞癌(papillary renalcell carcinoma，pRCC)，通常在男性中的发病率明显高于女性（约为1.9:1），且主要发病年龄集中在60至70岁之间。Xp11易位性肾细胞癌是一种相对罕见且侵袭性强的恶性肿瘤，其发病年龄相对较早，通常在20至30岁之间，且在女性中的发病率明显高于男性。驱动Xp11易位性肾细胞癌的关键突变是位于X染色体上的转录因子结合IGHM增强子3（TFE3 transcription factor binding to IGHM enhancer 3）与其他基因形成的融合基因。由于女性基因组中有两条X染色体，而男性只有一条，对于此类肾癌在女性中较高的发病率，一个直观的解释是该性别差异可能与额外的X染色体有关。然而，女性基因组中的两条X染色体会有一条在发育过程中因失去活性而只表达少量基因。究竟这个失活的X染色体能否产生致癌突变仍属未知。解决这个问题需要对女性基因组中两个X染色体的突变和表达分别进行分析，特别是在癌症背景下。在之前的研究中，来自Cheng-Zhong Zhang团队的鲍春旸博士针对全基因组测序数据开发了一种全新的生物信息学方法。该方法可以检测单条亲本染色体的突变，包括DNA拷贝数变异，重排和单碱基变异。在本文中，作者将这些方法应用于X染色体的分析，并得到以下发现。 TFE3基因融合驱动Xp11易位性肾细胞癌的关键突变是位于X染色体上的TFE3基因融合，包括X染色体内部的重组（左），X染色体与常染色体的易位（中）和复杂的基因融合（右）（Credit: Cell）首先，驱动Xp11易位性肾细胞癌的致癌突变既可以来源于有活性的X染色体（chrXa），也可以来源于失活的X染色体（chrXi）。因此，女性（基因组包含有活性的X染色体和失活的X染色体）比男性（基因组只包含有活性的染色体）发病率更高。其次，失活的X染色体主要通过与常染色体的易位（translocation）形成TFE3基因融合。对于有活性的X染色体，致癌突变既可以通过X染色体与常染色体之间的易位，也可以通过X染色体内部的重组产生。对于失活的X染色体，要产生致癌突变需要重激活致癌基因。作者推测后者只能通过失活的X染色体常染色体之间的易位来实现。为了验证这一推测，作者收集了203例已有的Xp11易位性肾细胞癌病例，包括复旦大学丁琛课题组的80例和四川大学曾浩课题组的64例。通过分析不同类型的TFE3基因融合，作者发现X染色体与常染色体形成的基因融合在女性和男性中的比例接近2:1。相比之下，X染色体内部重组形成的TFE3基因融合（来源于有活性的X染色体）在女性和男性中的比例接近1:1。上述结果表明，在女性患者中有活性和失活的X染色体参与TFE3基因融合的几率接近1:1。这一发现为解释女性中此类肾癌的高发病率提供了分子生物学依据。此外，作者也在由TFE3基因融合驱动的其他癌症中验证了类似的性别差异。这些发现证实了失活X染色体产生的突变和癌症性别差异之间的直接联系。 X染色体与常染色体形成的基因融合在女性（紫色）和男性（青色）中的比例接近2:1（Credit: Cell）研究进一步发现，失活的X染色体和常染色体共同参与的基因融合会导致相关染色体上出现大范围的转录失调。这种基因融合通过如下机制引发转录失调：在失活的X染色体部分被整合到常染色体上的基因会被重新激活（re-activation）；在常染色体上，一部分被整合到失活的X染色体的基因会受到位于X染色体失活特异性转录本（X Inactive Specific Transcript）的调控而沉默(silencing)。失活的X染色体与常染色体形成的染色体易位导致大范围的转录失调（Credit: Cell）最后，由于X染色体上包含许多必需基因，一旦这些基因的表达丧失，细胞将失去基本的生理功能。因此，在有活性的X染色体上，大片段的DNA缺失是细胞无法耐受的。相反，在失活的X染色体上，大片段的DNA缺失不会对细胞的生理功能产生直接影响，但X染色体与常染色体的重组可以对基因表达甚至细胞的生理功能产生间接影响。该研究首次阐明一个可以解释癌症性别偏差的基因组变异，首次证明一个体细胞变异可以逆转X染色体失活（这一过程在女性胚胎发育期间启动后一直稳定保持）。更广泛地说，失活X染色体产生的突变可能是在其他癌症中性别差异的基础。除了这些进展外，该研究也首次揭示了Xp11易位性肾细胞癌的全基因组特征。 Xp11易位性肾细胞癌的全基因组特征（Credit: Cell）参考文献 https://doi-org.libproxy1.nus.edu.sg/10.1016/j.cell.2024.07.038 责编|探索君排版|探索君文章来源|“BioArt” End 往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文 Cell | 是什么决定了细胞的大小？热文 Nature | 2024年值得关注的七项技术热文 Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文 CRISPR技术进化史 | 24年Cell综述

临床研究

2024-05-21

·PRNewswire

Aster Insights, ORIEN to Present Research Abstracts at the 60th ASCO Annual Meeting

Investigators will present four studies highlighting collaborations across ORIEN, Aster Insights, NIH TAMPA, Fla., May 21, 2024 /PRNewswire/ -- Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced the company and members of the Oncology Research Information Exchange Network® (ORIEN) will be presenting at the American Society of Clinical Oncology (ASCO) annual meeting, which will be held May 31 – June 4, in Chicago, IL. Four abstracts examining melanoma, kidney, gastrointestinal, and uterine cancers highlight the work of collaborators across ORIEN, Aster Insights, and the National Institutes of Health (NIH) with several authors contributing to more than one of these studies, demonstrating the importance of cross-functional, multidisciplinary research. "The abstracts chosen for presentation at ASCO highlight the unique and diverse investigations that can be launched when premier cancer institutions are collaborating and harnessing deep multimodal data," said Dr. Anand Shah, CEO of Aster Insights. "Robust representation across cancer types and patient demographics enables us to launch research that yields critical insights to better care for patients." Schedule of Aster Insights' ASCO Poster Presentations: Riya Patel. Genomic signature analysis and survival outcomes in cholangiocarcinoma (CCA) using oncology research information exchange network (ORIEN) database. Abstract 4101; Poster 81 Ahmad Tarhini. A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits. Abstract 9568; Poster 352 Juan Antonio Raygoza Garay. Unraveling the gene expression signatures with associated clinical outcomes in papillary renal cell carcinoma. Abstract 4558; Poster 253 Taylor Rives. Comparison of the clinical and genomic profiles of endometrial cancer in Appalachian and non-Appalachian patients. Abstract 5591; Poster 462 "We look forward to sharing our important work to construct an immune cell state atlas through ecotype analyses to foster a deeper understanding of the correlations between immune cell states and responsiveness to immune checkpoint inhibitors," said Ahmad Tarhini, MD, PhD of Moffit Cancer Center and Chair of the ORIEN Scientific Committee and ORIEN Immuno-Oncology Research Interest Group. "This collaborative effort draws on multidisciplinary expertise and rich clinicogenomic data from across ORIEN and Aster Insights, as well as the NIH." Aster Insights will be attending ASCO. Please contact us to request a meeting. About Aster Insights Aster Insights is the leading provider of scientific and clinical intelligence for oncology discovery. We partner with drug, biologics, diagnostics, and medical device developers to accelerate oncology product discovery and development. Aster Insights leads the Oncology Research Information Exchange Network® (ORIEN), a consortium of the nation's leading cancer centers that conduct Total Cancer Care®, the world's largest and longest running observational research study in oncology. Together, we are changing the way cancer is studied, treated, and prevented. Learn more at and follow us on LinkedIn and Twitter. SOURCE Aster Insights

ASCO会议免疫疗法临床研究